For Healthcare Professionals Outside the US
PIQRAY dosing and administration1
PIQRAY is a once-daily medication given in combination with fulvestrant1,2
Continue treatment until disease progression or
until unacceptable toxicity occurs.
*Tablets should
not be chewed, crushed, or split prior to
swallowing. No tablet should be ingested if it
is broken, cracked, or otherwise not
intact.
Certain adverse reactions may require dose modifications1,2
Dose interruptions may be required prior to dose
reductions
The PIQRAY dose may be reduced in increments of
50 mg†
If further dose reduction below 200 mg/d is
required, discontinue PIQRAY
†Only one dose reduction is
permitted for pancreatitis.
Please refer to the full Prescribing Information for dose interruption, reduction, or discontinuation of PIQRAY in specific adverse reactions. The management plan of each patient should be based on the individual benefit/risk assessment.
References:
1. Piqray®
(alpelisib)
EU Summary of Product Characteristics. Novartis;
2022.
2. André F,
Ciruelos E,
Rubovszky G,
et al. Alpelisib
for PIK3CA-mutated, hormone receptor-positive
advanced breast cancer.
N Engl J Med. 2019;380(20):1929-1940.
This is an international site for PIQRAY®
(alpelisib) and is intended for healthcare professionals
outside the US.